Cadence Neuroscience
Sammamish, US · Founded 2017 · Delaware corporation · 5 known investors
Cadence develops a neuromodulation system intended to be a more effective, less invasive treatment for people living with drug-refractory epilepsy. The medical device is designed to be adaptable to individual patient needs and was developed in collaboration with Mayo Clinic.
Founders & leadership
KL
Kent LeydeExecutive Officer, Director, Promoter
WD
Warren Douglas SheffieldExecutive Officer, Director, Promoter
Investors · 5
Reported raises · per SEC filings
Form D private placements▶$26MraisedFeb 2023 · 7 investors · BiotechnologyRule 506(b)
▶$26MraisedFeb 2023 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John HarrisDirector
- Kevin ChuDirector
- Kent LeydeExecutive Officer, Director
- Gerry BrunkDirector
- Warren Douglas SheffieldExecutive Officer
- Offering amount
- $26M
- Amount sold
- $26M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedSep 2019 · 1 investors · BiotechnologyRule 506(b)
▶$3MraisedSep 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kent LeydeExecutive Officer, Director, Promoter
- Warren Douglas SheffieldExecutive Officer, Director, Promoter
- Andrew FirlikDirector
- John HarrisDirector
- Offering amount
- $15M
- Amount sold
- $3M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶Undisclosed amountofferedJul 2017 · 1 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedJul 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kent LeydeExecutive Officer, Director, Promoter
- Warren Douglas SheffieldExecutive Officer, Director, Promoter
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.